QS Pharma

What QS Pharma does

Quotient Sciences operates as a private Contract Research, Development, and Manufacturing Organization (CRDMO) serving pharmaceutical and biotech sponsors. The company's service portfolio spans drug product development and manufacturing, early clinical development, pediatric formulation development, and commercial manufacturing, positioning it across the formulation-to-clinical-to-commercial lifecycle under a single operating entity. Its flagship offering, Translational Pharmaceutics®, is a proprietary methodology that integrates clinical trial conduct with real-time cGMP drug product manufacturing in a single workflow, allowing formulation adjustments to be made and tested within an ongoing clinical study rather than through separate, sequential development campaigns.

The firm maintains a transatlantic operating footprint with a UK office reachable at +44 (0)115 974 9000 and a US office reachable at +1 800 769 3518, and serves customers via enterprise field sales to pharma and biotech sponsors. Pricing is quote-based and tied to project scope rather than standardized SKUs, consistent with project-based contract services revenue mechanics typical of CRDMO engagements. Customer segment mix and named sponsor logos are not disclosed in the available data.

The most recent disclosed innovation is the advancement of an AI-designed drug product into clinical development, signaling that Quotient is beginning to apply generative or AI-assisted tools within its formulation and development pipeline. The underlying technical architecture, model ownership, vendor dependencies, and validation depth of this AI capability are not described in the input, so the move should be read as directional rather than as evidence of an AI-native operating model. No funding rounds, M&A activity, partnership announcements, or leadership changes are reported in the supplied data, limiting visibility into the company's current growth posture.

Name

QS Pharma

Legal name

Quotient Sciences

Website

https://qspharma.co.uk

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Quotient Sciences is a privately held pharmaceutical CRDMO providing integrated drug product development, GMP manufacturing, early clinical development, pediatric formulation, and commercial production services for pharma and biotech sponsors via its proprietary Translational Pharmaceutics® platform.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO/CRDMO)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Drug development services
• Contract manufacturing organization
• Clinical pharmacology research
• Formulation development services
• Small molecule development

Headquarters

HQ city

Delaware Water Gap

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Contract Research and Development Services: Integrated pharmaceutical development services spanning early clinical development, formulation development, and clinical manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies requiring drug development support from candidate selection through commercial supply.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Quotient Sciences is a pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated drug substance and drug product development services from candidate selection through commercial supply. Its core activities include pre-formulation, formulation development, analytical services, small-molecule API development and manufacturing, clinical trial manufacturing, and early clinical pharmacology studies, delivered across facilities in the UK and US.

Product overview

Quotient Sciences operates as a CRDMO (Contract Research, Development, and Manufacturing Organization) offering an integrated portfolio of pharmaceutical drug development services. The company provides a unified platform spanning four core interconnected services: Drug Product Development & Manufacturing (formulation development, clinical manufacturing, commercial production), Early Clinical Development (first-in-human trials, clinical pharmacology), Translational Pharmaceutics® Integrated Drug Development (integrating clinical activities with real-time cGMP manufacturing), and Pediatric Formulation Development (specialized pediatric solutions). The company emphasizes an integrated approach that connects these services to streamline the path from candidate selection through commercial supply.

Differentiator

Problem solved

Functional benefit

Brands

• Translational Pharmaceutics®: A unique integrated drug development approach that integrates clinical activities with real-time cGMP drug product manufacturing

Products and services

• Translational Pharmaceutics® Integrated Drug Development
• Drug Product Development & Manufacturing
• Early Clinical Development

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• IQVIA: World's largest CRO offering Phase I–IV clinical trial services plus real-world evidence and lab services — overlaps with Quotient's early clinical development and clinical pharmacology programs at a much larger scale.
• Thermo Fisher Scientific (PPD): Through its PPD clinical research business, Thermo Fisher offers global CRO services including Phase I clinical pharmacology — competes with Quotient's Early Clinical Development offering for pharma and biotech sponsors.
• Syneos Health: Biopharma solutions organization offering clinical development and commercial services — overlaps with Quotient's Early Clinical Development offering, particularly in Phase I clinical pharmacology and translational sciences.
• ICON plc: Global CRO providing Phase I–IV clinical research services plus laboratory and commercialization offerings — competes primarily with Quotient's Early Clinical Development arm for clinical pharmacology and first-in-human studies.
• Charles River Laboratories: Large diversified CRO/CDMO providing discovery, safety assessment, clinical, and manufacturing services — broader portfolio than Quotient but overlaps meaningfully in early clinical development and CDMO services for small molecules.
• Labcorp: Through its Labcorp Drug Development / Fortrea spin-off, offers global CRO and central laboratory services — competes with Quotient in clinical pharmacology, central lab, and Phase I services for pharma/biotech sponsors.

Emerging players

• Medpace: Mid-sized full-service CRO focused on Phase I–IV clinical trials for small-to-mid biotech sponsors — comparable customer profile and operational model for early clinical development work where Quotient competes.

Direct peers

• WuXi AppTec: Global CRDMO providing integrated drug discovery, development, and manufacturing services from preclinical through commercial — directly comparable integrated model serving pharma and biotech sponsors with end-to-end capabilities.
• Lonza: Leading global CDMO providing drug substance and drug product development and manufacturing across small molecules and biologics — competes with Quotient in formulation development, clinical manufacturing, and commercial supply for pharma and biotech sponsors.
• Catalent: Global CDMO offering formulation development, clinical and commercial manufacturing, and integrated drug development services — directly competes with Quotient in drug product development and manufacturing, particularly in small molecule formulation and clinical supply.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QS Pharma